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Study Characteristics
Study Treatment Dose N
Adams et al., 1995 USA Synvisc 3 weekly IA injections 25
Usual NSAID
therapy
Usual dose (x12wk) 32
Altman et al., 1998 USA Hyalgan 5 weekly IA injections 16
Naproxen 500 mg orally twice daily (x12 wk)* 16
Dickson et al., 2001 UK Synvisc 3 weekly IA injections 53
Diclofenac 100 mg orally once daily (x12 wk) 55
Petrella et al., 2002 Canada Suplasyn 3 weekly IA injections 25
Diclofenac 75 mg and 100 mg misoprostol
orally twice daily (x12wk)
26
Ishijima et al., 2012 Japan Suvenyl 5 weekly IA injections 91
Loxoprofen 60 mg orally thrice daily (x5 wk)** 80
Note: IA¼ intra-articular; wk ¼weeks; yr ¼ year; BMI ¼ Body Mass Index; VAS ¼ Visual
Index; nd ¼ no data; *subcutaneous sham injection; **no IA injection controlĂ
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Purpose: The efﬁcacy of intra-articular Hyaluronic acid (HA) for knee
osteoarthritis (OA) has been debated for over a decade. It has been
systematicallyevaluated inmeta-analyses,mostlyagainstplaceboor intra-
articular corticosteroids. However, it has never been compared in a meta-
analysis against oneof themost efﬁcacious andwidelyused treatments for
knee OA, i.e., NSAIDs. Furthermore, the favorable safety proﬁle of HA over
NSAIDs makes this comparison especially interesting. We aimed to assess
the efﬁcacy of HA in a pooled comparison to NSAIDs for knee OA.
Methods: We searched Medline, EMBASE, Google Scholar, ISI Web of
Science and Cochrane Database from inception to November 2012. We
also hand-searched review articles, manuscripts and supplements from
medical journals. We included all human randomized controlled trials
comparing HA with NSAIDs for knee OA. Two reviewers independently
performed data extraction and assessed the quality of each trial. We
computed effect sizes for pain, function, and stiffness (change from
baseline) for each study using the Hedges’ g statistic corrected for small
sample sizes. Effect sizes were pooled using random effects model.
Heterogeneity was assessed using I2 statistic. Sensitivity analysis was
performed by pooling trials reporting pain outcomes at 4 and 12 weeks
to check for the therapeutic trajectory.
Results: The 5 eligible trials included 712 participants (HA - 357;
NSAIDs - 355) with an age range of 61 to 67 years (Table 1). They were
published between 1995 and 2012. NSAIDs used in these trials were
from the same class. Four different HA preparations were used. Sample
sizes varied between 51 and 325. All trials except one were of 12 week
duration. Three had IA injections and one had subcutaneous injections
as control. Two trials were open-label. Dropout rates ranged from 2 to
30%. Five trials contributed to the pain analysis at last follow-up. Both
groups showed improvement from baseline. We found an effect size of
‑0.07 (95%CI -0.24, 0.10), not favoring either treatment (Table 2, Figure
1). There was no statistically signiﬁcant difference between the groups
at 4 and 12 weeks. Two trials contributed to the function and stiffness
analyses, and showed no statistically signiﬁcant differences between
the groups. Injection site pain was the most common adverse event
reported in the HA group, and gastrointestinal adverse events were
more common in the NSAIDs group.
Conclusions: This meta-analysis shows that HA injection is as
effective as continuous oral NSAIDs at 4 and 12 weeks. Given the
favorable safety proﬁle of HA over NSAIDs, this result is clinically
signiﬁcant and could transform knee OA care. Though some of the
trials may not have been powered to detect non-inferiority,
combining them increases the power for such an analysis. Our study
detected no safety concerns; however, the included trials had only
a short follow-up duration. Future randomized trials should incor-
porate a longer duration of follow-up and larger samples to fully
evaluate safety. It will be interesting to evaluate synergistic effect of
the two treatments.Age (yr) Female % BMI Duration (wk) Main Outcomes
61 68 27.0 12 VAS pain with motion
63 68 23.7
3 62 61 31.5 12 VAS pain on walking; WOMAC
pain, function, stiffness2 63 57 31.9
65 57 29.0 12 WOMAC pain, function,
stiffness; Lequesne Index64 55 29.0
67 36 29.5 12 WOMAC pain, function,
stiffness; VAS pain on walking66 42 29.4
nd nd nd 5 VAS pain
nd nd nd
Analogue Scale; WOMAC ¼Western Ontano & McMaster Universities Osteoarthritis
Figure 1. Forest plot for pain at the end of the trial.Ă
Table 2
Results for Pain, Stiffness and Function
Study Trials N Patients N Effect Size I2
Pain
All timepoints 5 712 -0.07 (-0.24, 0.10) 16%, low
4 weeks 3 547 0.01 (-0.15, 0.18) 0%, no
12 weeks 4 541 -0.05 (-0.28, 0.17) 30%, low
Stiffness 2 159 0.03 (-0.27, 0.34) 0%, no
Function 2 159 -0.08 (-0.39, 0.23) 0%, no
Note: CI ¼ Conﬁdence Interval; I2 ¼ Heterogeneity Score
Figure 1. [PRG4] in ﬂare-SF after IA HA or corticosteroid injection. [PRG4] SEM in
normal (NL) SF (N¼29) shown by black lines. Samples selected for friction testing (HA
ﬂare only) are circled.
Figure 2. HAMW distribution in N¼4 PRG4-deﬁcient ﬂare-SF samples selected for
friction testing and N¼14 normal (NL) SF (#¼ p<0.05)
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EFFECT OF FLARE REACTION TO INTRA-ARTICULAR INJECTION ON
CARTILAGE LUBRICATING ABILITY OF HUMAN SYNOVIAL FLUID
T.E. Ludwig, J.R. McAllister, V.M. Lun, J.P. Wiley, T.A. Schmidt. Univ. of
Calgary, Calgary, AB, Canada
Purpose: In synovial ﬂuid (SF), proteoglycan 4 (PRG4) and hyaluronan
(HA) act synergistically to contribute to the boundary lubrication of
articular cartilage in a dose-dependent manner. Alterations in PRG4 and
HA levels in SF can lead to compromised boundary lubrication, which
can be restored in vitro by lubricant supplementation. Intra-articular
(IA) injections of HA and corticosteroid are common treatments for
osteoarthritis (OA). In vitro studies have suggested that IA HA alonemay
be insufﬁcient to provide chondroprotection, as evidenced by increased
chondrocyte apoptosis during cartilage-on-cartilage friction testing
relative to native SF. A recent review highlighted the small beneﬁt of IA
HA treatment and increased risk of ﬂare reaction (deﬁned as a hot,
painful, swollen knee after injection). The effects of a reaction to IA
treatment on SF lubricant content and lubricating ability are unknown.
The objectives of this study were to 1) quantify PRG4 and HA content in
OA SF after a ﬂare reaction to IA treatment and 2) assess the cartilage
boundary lubricating ability of ﬂare-SF deﬁcient in PRG4, with and
without supplementation with PRG4HA.
Methods: Knee SF was collected from OA patients’ requiring aspiration
after corticosteroid or HA injection (11 days after injection, N ¼ 14.)
PRG4 and HA concentrations in normal (NL, N ¼ 29) and ﬂare-SF were
measured by sandwich enzyme linked immunosorbent assay. HA
molecular weight (MW) distribution was determined by agarose gel
electrophoresis. Lubricating ability of PRG4-deﬁcient ﬂare-SF, PRG4-
deﬁcient ﬂare-SF supplemented with normal levels of PRG4HA, and
NL SF was tested in a normal human cartilage-on-cartilage friction test.
Static, mstatic,Neq, and kinetic, <mkinetic,Neq>, friction coefﬁcients
were calculated.
Results: Flare-SF PRG4 and HA concentrations ranged from below
normal to super-physiological. Four samples deﬁcient in PRG4 ([PRG4],
below the average NL concentration) were selected for friction testing;
all 4 were reactions to IA HA (Fig. 1). HA concentration in the friction
tested ﬂare-SF did not differ from NL (p¼0.5, not shown), while HAMW
was shifted slightly towards the smaller size range (Fig. 2).
<mkinetic,Neq> in PRG4-deﬁcient ﬂare-SF (Fig. 3) was not altered
compared to NL, and no changes were observed with PRG4 or PRG4+HA
supplementation (p¼0.77-1.0).
Conclusions: These results demonstrate that some ﬂare-SF exhibits
altered lubricant composition after reaction to IA injection, as has beenpreviously observed in ACL injury and chronic OA, but can still retain
normal boundary lubricating ability. A dramatic shift towards lower HA
MW in chronic OA SF deﬁcient in PRG4 has previously been observed; an
HA distribution closer to normal SF, as observed here, could contribute to
the normal lubricating ability observed. Other characteristics of PRG4,
including glycosylation and size distribution, remain to be evaluated and
compared between healthy and diseased SF, and may have effects on SF
lubricating ability. Evaluation of OA SF after IA injection over a longer
time course, along with further analysis of PRG4 characteristics, will
provide further insight into effects of inﬂammation on joint lubrication.
